Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

High-Risk Ocugen Needs Good Trial Results to Survive

By Chris Lau, InvestorPlace Contributor

Ocugen stock has fallen far, and needs positive trial results for its OCU300 treatment to turn things around. For now, it's a high-risk play.

Alibaba’s Growth Will Just Keep Getting Better

By Chris Lau, InvestorPlace Contributor

Alibaba is looking attractive thanks to its growth potential and recent cash raise. Use this dip to buy some shares in Alibaba stock.

Aurora Cannabis Must Win Back Investors’ Trust in 2020

By Chris Lau, InvestorPlace Contributor

To avoid further suffering, Aurora Cannabis must win back trust. To help ACB stock rally, it must grow revenue and launch 2.0 goods.

Why Shopify Is Set to Smash Quarterly Earnings Expectations

By Chris Lau, InvestorPlace Contributor

Shopify dominated Black Friday and Cyber Monday sales, and the company is set for international growth. Shopify stock is one to buy.

EV Growth Makes Plug Power’s Prospects Look Bright Through to 2024

By Chris Lau, InvestorPlace Contributor

Buyers are holding more PLUG stock after it won a $172 million order and Plug Power's addressable market continues to expand.

Load More